Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-485232 · 4 trials · 4 indications
Tumor response rate (RR) is defined as the percentage of participants achieving either a complete or partial response. Response was at least one measurable lesion as defined by response evaluation criteria for solid tumors (RECIST) criteria or a cutaneous or subcutaneous lesion of at least 1 centimeter (cm) in diameter in one dimension. A distinction was drawn between responses that are confirmed at a repeat assessment and those that are not. If there were unconfirmed responses, then a sensitivity analysis was performed excluding participants with unconfirmed responses. Analysis was performed by both Investigator and independent review committee (IRC). The results were compared and a confirmatory analysis has been presented.
| Arm | Type | Description |
|---|---|---|
| SB-485232+Rituximab | EXPERIMENTAL | Rituximab 375 milligrams per square meter (mg/m\^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started. |
| Name | Type | Description |
|---|---|---|
| SB-485232 | DRUG | - |
| Rituximab | DRUG | Rituximab 375 mg/m\^2 will be administered by IV infusion. |
Inclusion criteria: * Patients must have melanoma that has spread beyond the original location and has not yet been treated. * Tissue from the spreading melanoma should have been tested to confirm it is melanoma. Exclusion criteria: * Patients having hepatitis or HIV infection. * Taking corticost...
Top 20 of 51 competitors
SB-485232 is an investigational oncology drug being studied for solid tumor cancer, melanoma, lymphoma, and non-Hodgkin lymphoma. It is a small molecule developed by GSK plc. Clinical trials have evaluated it in adults with these conditions, though it remains in clinical development and is not approved.
SB-485232 is developed by GSK plc, a pharmaceutical company traded on the New York Stock Exchange under the ticker GSK. The company has sponsored clinical trials of this investigational drug in oncology indications.
SB-485232 is in Phase 1 clinical development. Multiple Phase 1 trials have been completed, along with one Phase 2 trial in metastatic melanoma. All trials are completed, and the drug remains investigational, not approved for any use.
SB-485232 has completed several clinical trials. NCT00085878 studied daily subcutaneous injections in adults with solid tumors. NCT00085904 evaluated intravenous dosing every 28 days in solid tumors or lymphomas. NCT00107718 assessed anti-tumor activity in previously untreated metastatic melanoma. NCT00500058 examined safety and biological activity in lymphoma and non-Hodgkin lymphoma.
Yes, SB-485232 is also known as recombinant human interleukin-18. One clinical trial, NCT00500058, explicitly describes SB-485232 as recombinant human interleukin-18, indicating these names refer to the same investigational drug.